SGLT 2 INHIBITORS
Clinical trials for SGLT 2 INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new SGLT 2 INHIBITORS trials appear
Sign up with your email to follow new studies for SGLT 2 INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Matched conditions: SGLT 2 INHIBITORS
Phase: PHASE1, PHASE2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Could a diabetes drug shield Kids' kidneys?
Disease control OngoingThis study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, an…
Matched conditions: SGLT 2 INHIBITORS
Phase: NA • Sponsor: Al-Quds University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Diabetes drug eye risk under microscope
Knowledge-focused OngoingThis study looks at how newer diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) affect the eyes of people with type 2 diabetes. Researchers will monitor 40 adults who take metformin and are starting these newer drugs. The goal is to see if these drugs cause any …
Matched conditions: SGLT 2 INHIBITORS
Sponsor: University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC